Comparison of Adsorption and Encapsulation Methods in Preparation of rSAG1-loaded PLGA Nanospheres as Particulate Vaccine against Toxoplasma gondii Infection

Introduction: Despite all progress in vaccine research against toxoplasmosis, subunit vaccines still deal with poor immunogenicity, which could be overcome by using efficient delivery vehicles like PLGA. The proteinaceous nature of antigens makes the loading of protein more challenging than chemical medicines. Here, we prepared rSAG1-PLGA by adsorption and encapsulation methods and compared their characterizations. Methods and Results: Blank PLGA and rSAG1-encapsulated PLGA nanospheres were prepared using double emulsion solvent evaporation technique at room temperature. rSAG1-adsorbed PLGA nanospheres were prepared by incubating a suspension of freeze-dried blank PLGA with rSAG1 in PBS (pH 7.4) and it was mixed at 4°C overnight. Size, PDI, zeta potential, preparation yield, and adsorption/encapsulation efficiency of all prepared PLGA nanospheres were characterized and summarized in table below:   Formulation Size (nm) PDI* Zeta potential (mV) A/E efficiency (%) Yield (%) Blank PLGA 438 ± 11 0.12 ± 0.01 -5.56 ± 0.68 - 86.8 ± 3.56 rSAG1-adsorbed  PLGA 486 ± 9.9 0.14 ± 0.02 -1.00 ± 0.33 69.73 ± 3.05 87.4 ± 2.7 rSAG1-encapsulated PLGA 471 ± 8.5 0.20 ± 0.04 -4.66 ± 0.6 46.93 ± 2.51 86.8 ± 2.86 *Poly Dispersity Index, A; adsorption, E; encapsulation Moreover, in vitro release profile of both PLGA nanospheres during 4 weeks demonstrated more or less similar release pattern (zero-order release patterns). However, rSAG1 release in rSAG1-encapsulated PLGA happened slower than release in rSAG1-adsorbed one. Conclusions:  Based on obtained size, both rSAG1-adsorbed and rSAG1-encapsulated particles could be efficiently taken up by presenting cells. Higher efficiency of adsorption than encapsulation makes adsorption method more economic in large scale. Protein during encapsulation process faces some stability problems due to exposure to harsh mechanical thermal and chemical stresses affecting protein integrity and immunogenicity. Therefore, protein adsorption would be applied as a suitable method for protein loading. We are going to evaluate the efficiency of both particles in eliciting immune responses in BALB/c

Co-delivery of PLGA nanoparticles loaded with rSAG1 antigen and TLR ligands: An efficient vaccine against chronic toxoplasmosis

International audienceAlthough vaccination is a promising approach for the control of toxoplasmosis, there is currently no commercially available human vaccine. Adjuvants such as delivery vehicles and immunomodulators are critical components of vaccine formulations. In this study, Poly (D, l-lactide-co-glycolide) (PLGA) nanoparticles were applied to serve as delivery system for both surface antigen-1 (SAG1), a candidate vaccine against toxoplasmosis and two TLR ligands, monophosphoryl lipid A (MPL) and imiquimod (IMQ), respectively. Compared to rSAG1 alone, CBA/J mice immunized with rSAG1-PLGA produced higher anti-SAG1 IgG antibodies titers. This response was increased by the co-administration of IMQ-PLGA (p < 0.01). Compared to IMQ-PLGA co-administration, MPL-PLGA co-administration further increased the humoral response (p < 0.01) and potentiated the Th1 humoral response. Compared to rSAG1 alone, rSAG1-PLGA, or rSAG1-PLGA mixed with IMQ-PLGA or MPL-PLGA similarly enhanced the cellular response characterized by the production of IFN-γ, IL-2, TNF-α and low levels of IL-5, indicating a Th1-biased immunity. The induced immune responses, led to significant brain cyst reductions (p < 0.01) after oral challenge with T. gondii cysts in mice immunized with either rSAG1-PLGA, rSAG1-PLGA + IMQ-PLGA, rSAG1-PLGA + MPL-PLGA formulations. Taken together the results indicated that PLGA nanoparticles could serve as a platform for dual-delivery of antigens and immunomodulators to provide efficacious vaccines against toxoplasmosis